findmyKOL

Mark Juzych, MD, MHSA

Basic profile

Wayne State University

ORCID↗NPI↗
✓ Full record
RegionDetroit, MI · MidwestSpecialtyOphthalmologyFocusOphthalmology
Active KOLfindmyKOL type: RegionalLatest publication2025Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Mark Juzych is an Ophthalmology physician affiliated with Wayne State University. OpenAlex indexes 124 publications with 2,524 citations (h-index 26).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
124publications

Distinct works indexed by OpenAlex, matched via ORCID.

2,524citations

Total citations across indexed works.

26h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
9companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Kresge Eye Institute
4717 St Antoine
Detroit, MI 48201

Telephone

313-577-8900

Provider last certified this registry record 13 Sept 2022.

View the NPPES registry record

Industry payments

9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Sensory organs

    84.2%
    Prostaglandin Analog38.2%
    Latanoprost83%Lumigan13%Travoprost3%Zioptan1%
    Part D<11 patients
    alpha-Adrenergic Agonist23.4%
    Brimonidine Tartrate72%Combigan16%Brimonidine Tartrate-Timolol9%Alphagan P4%
    Part D≥186 patients

    + 5 more classes in this area

  • Cardiovascular

    11.6%
    Beta blocker11.6%
    Timolol Maleate100%
    Part D≥128 patients
  • Cancer & immunology

    1.4%
    Calcineurin inhibitor1.4%
    Cyclosporine36%Restasis34%Restasis Multidose30%
    Part D<11 patients
Where care is delivered (Part B)2.5% facility · 97.5% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”